Eisai and Biogen have received marketing authorisation from the European Commission (EC) for Leqembi (lecanemab) to treat Alzheimer's.

Mural Oncology is halting development of its lead IL-2 therapy and enacting major layoffs after its second trial failure this ...

Irish medical and pharmaceutical exports to the US have seen a surge, with a year-on-year increase above 450% in February ...

AD is a growing market with an impressive pipeline of new products from current and future players in the field.

Boehringer and Cue Biopharma have entered a strategic research partnership and licence agreement for the latter’s CUE-501.

J&J is projecting a $400m hit due to US tariffs in 2025, but reaffirmed its profit outlook while raising its sales forecast.

BMS could soon face competition in the HCM space as Cytokinetics awaits a marketing application decision from the FDA for ...

The latest trends in cell therapies indicate a growing confidence in their effectiveness, an expansion of applications beyond oncology and significant market growth potential. However, the industry ...

One concern with in vivo CAR-Ts is the potential insertional mutagenesis of the lentiviral DNA payload, causing secondary cancers.

At the ESCMID Global conference in Austria, the development of climate-informed infectious disease risk management systems was discussed.

Concerns over a potential US recession this year are growing as investors assess the impact of Trump's tariff policies.

Coherus BioSciences has completed the sale of its Udenyca (pegfilgrastim-cbqv) franchise to Intas Pharmaceuticals for up to $558.4m.